Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...

Johnson & Johnson (NYSE: JNJ) today announced data from two studies highlighting that a DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and ...

Forest plots of daratumumab OS efficacy (vs. therapies without daratumumab) according to (A) low- and (B) high-physical function. The study analyzed data from 1,804 patients enrolled in three ...

PF-07248144 (KAT6 inhibitor): A rapid oral presentation will highlight dose optimization data from an ongoing Phase 1 study for PF-07248144, a potential first-in-class KAT6 inhibitor, in patients ...

ELREXFIO: Initial safety and efficacy results from Part 1 of the ongoing MagnetisMM-6 study of ELREXFIO in combination with daratumumab and lenalidomide in patients with newly diagnosed MM that are ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...

Bupropion XL: The typical starting dosage of bupropion XL for treating depression is 150 mg once per day. After 4 days, your doctor may increase your dosage to 300 mg per day (usually in the morning).

The rate of grade 3/4 TEAEs were 40.4% and 30.1% for daratumumab and active monitoring, respectively. Treatment discontinuation due to a TEAE occurred in 5.7% of patients on daratumumab.

Johnson & Johnson (NYSE: JNJ) today announced data highlighting that DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease ...

The CHMP recommendation for daratumumab is supported by data from the Phase 3 PERSEUS (NCT03710603) study, 4 evaluating D-VRd induction and consolidation therapy, and daratumumab with lenalidomide ...